Gensia Splits Up
Gensia has long been a model of a discovery-stage biotech, funding its research and simultaneously building a market presence through acquiring and marketing a suite of low-margin niche therapeutics with the intention of adding its own, internally-developed drugs to its product mix later on.
You may also be interested in...
TransEnterix hires Shameze Rampertab as its new CFO and said it expects “modest growth” in Q3 and Q4.
Keeping Track: Viltepso Earns Priority Review Voucher; Manufacturing Trips Fennec; Eagle Drops Ryanodex Exertional Heat Stroke Bid
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
CureVac raised hundreds of millions of dollars this year before its $213m initial public offering as its mRNA vaccine technology moved into the COVID-19 spotlight. Its stock price tripled on its debut.